Trial Watch—Oncolytic viruses and cancer therapy Review uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Cell Transformation, Neoplastic
  • Molecular Targeted Therapy
  • Neoplasms

abstract

  • Oncolytic virotherapy relies on the administration of non-pathogenic viral strains that selectively infect and kill malignant cells while favoring the elicitation of a therapeutically relevant tumor-targeting immune response. During the past few years, great efforts have been dedicated to the development of oncolytic viruses with improved specificity and potency. Such an intense wave of investigation has culminated this year in the regulatory approval by the US Food and Drug Administration (FDA) of a genetically engineered oncolytic viral strain for use in melanoma patients. Here, we summarize recent preclinical and clinical advances in oncolytic virotherapy.

publication date

  • February 2016

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4801444

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2015.1117740

PubMed ID

  • 27057469

Additional Document Info

start page

  • e1117740

volume

  • 5

number

  • 2